VIRACTA THERAPEUTICS INC (VIRX)
US92765F1084 - Common Stock
Top movers in Wednesday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Which stocks are experiencing notable movement on Wednesday?
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Gapping stocks in Monday's session
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients...
VIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023
VIRX stock results show that Viracta Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed...
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1,...
Viracta gets orphan drug status for Nana-val for EBV tumors (NASDAQ:VIRX)
Viracta Therapeutics (VIRX) has received FDA orphan drug designation for Nana-val in treatment of Epstein-Barr virus-positive solid tumors. Read more here.
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further...
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell...
Viracta Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
Preliminary clinical data from patients with relapsed/refractory EBV+ peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and...
Viracta Therapeutics to Host R&D Day on October 4, 2023
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...
Viracta Therapeutics Announces New Employment Inducement Grant
SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Achieved efficacy threshold to advance Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma into Stage 2 becoming the leading indication in...
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+...
Viracta Therapeutics gets new chief medical officer (NASDAQ:VIRX)
Clinical-stage precision oncology company, Viracta Therapeutics (VIRX) appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer or CMO, effective immediately. Dr
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the...
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and...
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma accelerating globally; update on first lymphoma subtype that may advance...
Viracta Therapeutics CMO Lisa Rojkjaer, M.D to depart (NASDAQ:VIRX)
Viracta Therapeutics (VIRX) said on Tuesday that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company to pursue another opportunity, effective May 5,...
Viracta Therapeutics Announces Departure of Chief Medical Officer
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and...